Is Risperidone Safe for a Child?

Risperidone is FDA-approved for use in children as young as five, but “safe” depends heavily on what it is being prescribed for, at what dose, for how long, and how carefully the child is monitored. It is the most-studied antipsychotic in pediatric medicine, and for specific conditions like severe irritability in autism, it has strong evidence of benefit. Yet it carries a documented list of side effects that range from rapid weight gain to hormonal disruption to concerns about bone development. Whether those risks are acceptable is not a yes-or-no question; it is a conversation that depends on the severity of the child’s symptoms and on whether the prescribing doctor is tracking the right things along the way.

What Risperidone Is Actually Approved for in Children

In the United States, risperidone has FDA approval for three pediatric uses: irritability associated with autism spectrum disorder in children aged 5 to 16, schizophrenia in adolescents aged 13 to 17, and bipolar mania in children aged 10 to 17. Outside those specific indications, any prescription is considered off-label. That does not mean it is illegal or unsupported by evidence, but it does mean the drug has not gone through the full regulatory review process for that particular condition.

Off-label use is common. A study of Texas Medicaid recipients found that roughly 60 to 67 percent of antipsychotic prescriptions for children were off-label between 2013 and 2016, and more than half of those off-label users had an ADHD diagnosis rather than one of the approved indications.¹ Among all second-generation antipsychotics, risperidone had the highest rate of guideline-adherent prescribing, but that bar was not especially high; community clinicians frequently prescribed outside established recommendations.² If your child’s doctor is prescribing risperidone for something other than autism-related irritability, schizophrenia, or bipolar mania, that is not unusual, but it is worth asking what evidence supports the decision.

How Well It Works for Autism-Related Irritability

The strongest evidence for risperidone in children comes from trials involving kids with autism who have serious behavioral problems: tantrums, aggression, and self-injury. In the landmark trial published in the New England Journal of Medicine, eight weeks of risperidone reduced irritability scores by about 57 percent, compared with 14 percent for placebo. About 69 percent of children on the drug were rated as “much improved” or better.³ Those are meaningful numbers for families dealing with behaviors that can make daily life unmanageable.

A follow-up study tracked children for about 21 months and found that the behavioral improvements persisted, including gains in social skills measured by a standard adaptive behavior scale. Irritability scores remained lower in children who continued risperidone. But the longer treatment continued, the more pronounced the weight gain became.⁴ A recent head-to-head trial comparing risperidone with aripiprazole (the other FDA-approved medication for this indication) found similar reductions in irritability and overall autism severity between the two drugs, though risperidone raised prolactin levels while aripiprazole lowered them.⁵ That hormonal difference matters, as we will get to shortly.

Use for ADHD and Disruptive Behavior

Many children receive risperidone not for autism but for aggression and defiance tied to ADHD, oppositional defiant disorder (ODD), or conduct disorder. An open-label study of children with conduct disorder found that 80 percent were classified as responders after risperidone treatment, with improvements in inattention, hyperactivity, and oppositional behaviors.⁶ When added to methylphenidate (the standard ADHD stimulant) in children with ADHD and ODD, risperidone improved behavioral symptoms more than the stimulant alone, though it also raised weight and prolactin levels.⁷

These results are real, but the evidence base is thinner than for autism, and the risk-benefit calculation shifts when a child’s diagnosis does not carry FDA-approved backing. If your child is prescribed risperidone primarily for behavioral problems associated with ADHD, it is reasonable to ask whether behavioral interventions have been tried first, and whether the severity of the behavior justifies the metabolic and hormonal trade-offs.

Weight Gain and Metabolic Effects

Weight gain is the most consistent and well-documented side effect in children taking risperidone, and it is not subtle. In a study of young children with autism, the average weight gain over 24 weeks was about 5.4 kilograms (roughly 12 pounds). At the start, about 61 percent of the children had a normal weight classification; by week 24, fewer than 30 percent still did. Waist circumference, blood sugar, insulin levels, and a marker of insulin resistance all rose significantly. Seven children met criteria for metabolic syndrome at baseline; by week 16, twelve additional children crossed that threshold.⁸

A more recent prospective study of children with various neurological disorders on risperidone found that over half developed at least one metabolic side effect within six to eight weeks. About a third developed abnormal lipid levels. Perhaps most concerning, the proportion of children classified as pre-diabetic rose to about 40 percent after just six to eight weeks of treatment, with one child meeting criteria for diabetes.⁹ These are not rare complications in a small fraction of children; metabolic changes appear to be the rule rather than the exception, especially in the early months of treatment.

Hormonal Effects and Prolactin

Risperidone is one of the strongest prolactin-raising antipsychotics on the market, and this matters more in children and adolescents than in adults. Prolactin is a hormone normally involved in lactation, but in elevated amounts it can interfere with sexual development, reproductive hormones, and bone formation. In a study of males aged 10 to 20 treated with risperidone for autism or behavioral disorders, 47 percent had elevated prolactin levels, compared with just 2 percent of a comparison group not on the drug. About 43 percent of the risperidone group developed gynecomastia (breast tissue enlargement), and 14 percent reported sexual dysfunction.¹⁰

A separate analysis found that children and adolescents taking risperidone had about five times the risk of gynecomastia compared to non-users.¹¹ For a teenage boy, developing breast tissue can be profoundly distressing. Many cases of elevated prolactin are asymptomatic, meaning the child does not have obvious symptoms but the hormonal disruption is still occurring. This is why routine blood work matters, even when a child seems to be tolerating the medication well on the surface.

Concerns About Bone Health

The prolactin elevation creates a downstream worry that gets less attention than weight gain but may matter more over a lifetime. Elevated prolactin suppresses the hormonal signals that drive sex hormone production, and sex hormones are critical for building bone density during childhood and adolescence. A cross-sectional study of boys found that prolactin levels were negatively correlated with bone mineral density at the wrist, meaning higher prolactin predicted weaker bones.¹²

A recent review of medication-related impacts on pediatric bone health flagged risperidone specifically, noting that the drug’s prolactin-raising properties can inhibit the hormonal axis responsible for bone formation during critical growth periods. The concern is not just about current fracture risk but about whether children who take risperidone for years may enter adulthood with lower peak bone density, raising their lifetime risk of osteoporosis.¹³ This is still an area where the long-term data are incomplete. Most of the evidence comes from cross-sectional studies and biological reasoning rather than from following large groups of children into adulthood. But the concern is biologically plausible enough that it deserves monitoring, especially when a child has been on risperidone for more than a year.

Movement Disorders and Seizure Risk

Older antipsychotics were notorious for causing tardive dyskinesia, a condition of involuntary muscle movements that can become permanent. Risperidone carries a lower risk. In a pooled analysis of three large one-year studies of children with disruptive behavior disorders, only one child met the formal research criteria for tardive dyskinesia after a dose reduction, and the symptoms resolved without treatment changes. Two others had transient movement symptoms that went away after stopping the drug. Overall movement-disorder scores were low throughout.¹⁴ Low risk is not zero risk, but for most children at standard doses, the movement-disorder concern is modest.

Seizures are a different story. A large nested case-control study in Korea found that children using antipsychotics, including risperidone, had a significantly elevated seizure risk compared to non-users. The risk increased further when children were taking more than one antipsychotic simultaneously, and it was highest in recent initiators of therapy.¹⁵ This matters most for children who already have a seizure history or neurological conditions that lower the seizure threshold.

Heart Rhythm Considerations

A systematic review of cardiac safety across antipsychotics in children and adolescents concluded that risperidone showed minimal to no significant prolongation of the QTc interval, which is the standard marker for drug-induced heart rhythm risk. That put risperidone in a more favorable position than some alternatives like quetiapine, olanzapine, and ziprasidone.¹⁶ However, a study looking specifically at children with ADHD found that risperidone did increase certain ECG markers, and the effect was amplified when risperidone was combined with methylphenidate.¹⁷ For most children, the cardiac risk appears low, but a baseline ECG before starting treatment and periodic follow-up makes sense, especially when a child is on multiple medications.

Why Some Children React More Than Others

Risperidone is broken down in the liver primarily by an enzyme called CYP2D6, and the gene for this enzyme varies quite a bit across the population. Some people are “poor metabolizers” who process the drug slowly, allowing it and its active breakdown product to build up in the blood. Others are “ultrarapid metabolizers” who clear it quickly. In children, poor and intermediate metabolizers had roughly 2.4 times the odds of experiencing adverse effects compared to normal and ultrarapid metabolizers, even after accounting for age, sex, and starting dose.¹⁸

Newer research is refining this picture further. Certain gene variants, particularly ones more common in people of African descent, behave differently than current pharmacogenetic guidelines assume. One variant confers more than four times the metabolic activity of the standard version of the gene, meaning carriers may need different dosing than guidelines suggest.¹⁹ Pharmacogenetic testing before starting risperidone is not yet standard practice, but it is increasingly available and can help explain why one child tolerates the drug with no issues while another at the same dose develops significant side effects.

The Monitoring Gap

Given the metabolic, hormonal, and other risks described above, you would expect rigorous tracking of weight, blood sugar, lipids, and prolactin in every child on risperidone. The reality falls short. An evaluation of a pediatric clinic found that only 13 percent of patients had documented baseline monitoring that included weight, blood pressure, and a fasting lipid panel before starting an antipsychotic. Not a single patient had a fasting blood sugar recorded at any point during treatment. Follow-up monitoring declined over time rather than improving.²⁰

This gap matters more than any single side effect, because many of risperidone’s most concerning effects are caught through lab work, not through a parent noticing something is wrong. A child’s prolactin can be elevated for months without visible symptoms. Blood sugar can creep upward before anyone notices. If your child is taking risperidone and the prescribing provider is not ordering regular blood work at minimum every few months, especially in the first year, the monitoring is falling below what the evidence supports.

What Happens When You Stop

Discontinuing risperidone introduces its own set of challenges. A randomized placebo-controlled discontinuation study of children who had been on risperidone for at least a year found that stopping the drug was associated with significant deterioration in verbal aggression, teacher-rated behavior, and clinician-rated functioning. About 56 percent of participants in the discontinuation group relapsed, forcing them to leave the study early. On the positive side, those who stopped risperidone saw improvements in weight, BMI, waist circumference, glucose, insulin, and prolactin levels.²¹ In other words, 44 percent of children who had been on risperidone for over a year successfully came off it without significant behavioral decline, while the rest genuinely needed it to maintain stability.

Abrupt discontinuation carries additional risk. Case reports describe withdrawal-emergent dyskinesia, involuntary movements that appear after suddenly stopping risperidone, including mouth movements, neck twisting, and abnormal eye movements in children.²² These episodes are generally self-limiting but can be alarming for families and children. The practical takeaway: if the decision is made to stop risperidone, a slow taper supervised by the prescriber is essential. Do not stop abruptly.

How Risperidone Compares to Aripiprazole

The most common question parents and clinicians ask is whether aripiprazole, the other FDA-approved antipsychotic for irritability in autism, is a safer bet. On behavioral outcomes, head-to-head trials consistently show similar efficacy. Weight gain appears comparable in short-term studies. In a trial comparing the two in preschool children with disruptive behavior and ADHD, rates of improvement were not significantly different between the drugs, and neither was the amount of weight gained.²³

The meaningful difference is prolactin. Risperidone consistently and substantially raises prolactin, while aripiprazole tends to lower it. In the randomized trial comparing both drugs for autism-related irritability, prolactin increased in the risperidone group and decreased in the aripiprazole group, despite similar behavioral outcomes.⁵ For a child who responds well to risperidone and has normal prolactin on monitoring, there may be no reason to switch. But for a child whose prolactin is rising, or who develops gynecomastia or other signs of hormonal disruption, aripiprazole is the logical alternative. This is exactly the kind of nuance that only shows up when the prescriber is tracking lab work.

What Practical Questions to Bring to Your Child’s Doctor

The evidence does not point to risperidone being categorically unsafe for children, nor does it suggest it should be given casually. It is a powerful medication with real benefits for specific conditions and real costs that demand active management. A retrospective study found that about 30 percent of pediatric risperidone patients experienced at least one adverse event, with weight gain and involuntary movement symptoms being the most frequent.²⁴ The conversation with your child’s provider should cover several areas:

Indication clarity: Is this an FDA-approved use, and if not, what evidence supports the off-label prescription?
Baseline labs: Are weight, blood pressure, fasting glucose, lipid panel, and prolactin being measured before starting?
Follow-up schedule: How often will labs be repeated? Every three months in the first year is a reasonable expectation.
Duration plan: Is there a defined period after which a trial discontinuation will be considered?
Genetic testing: Would pharmacogenetic testing for CYP2D6 be appropriate, especially if the child has had unusual reactions to medications before?
Alternative options: Has aripiprazole been considered, particularly given the prolactin difference? Have non-pharmacological interventions been fully explored?

A child with severe self-injurious behavior who responds dramatically to risperidone may be in a genuinely different risk-benefit situation than a child with mild oppositional behavior being prescribed the drug out of convenience. The medication’s profile does not change between those two scenarios, but the threshold for accepting its side effects certainly does.